THALES
Thales, the leading global technology and security provider, today launched the SafeNet eToken Fusion series, a new set of USB tokens combining Fast IDentity Online 2.0 (FIDO2) with PKI/CBA in a single authenticator. Thales’s new tokens are designed to protect Microsoft Azure Active Directory (Azure AD) users against account compromise and provide stronger security for access to cloud and web applications. The SafeNet eToken Fusion Series enables organisations to utilize phishing-resistant passwordless authentication methods, improving security for enterprise resources accessed from any device.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230425005040/en/
@Thales
Along with protecting against rising phishing threats, SafeNet eToken Fusion Series helps organisations meet their compliance needs for emerging cybersecurity standards. PKI/CBA and FIDO2 are the only two authentication methods recognised as phishing-resistant by U.S. EO 14028. This expands the reach of the Thales portfolio of industry-compliant authenticators, including the IDPrime FIDO Series.
Haider Iqbal, IAM Director of Product Marketing at Thales: “Many organisations have heavily invested in PKI infrastructure to secure access to their internal resources. They want to leverage PKI to secure access to cloud based resources or move to a modern form of authentication (FIDO2) while maintaining the usage of PKI for digital signature, data encryption. The SafeNet eToken Fusion Series provides the best of both FIDO and PKI worlds, and we are thrilled to equip customers with a solution that ensures enhanced security and compliance measures for access to their Azure AD resources.”
Natee Pretikul, Principal Product Management at Microsoft, Identity and Network Access: “Supporting phishing-resistant authentication methods is core to our mission to protect users against account compromise. The Microsoft team has been hard at work to extend our Azure AD capabilities, providing support for certificate-based authentication (CBA) along with Conditional Access Authentication Strength. We are pleased to announce that, Azure Active Directory combined with Thales new phishing-resistant hybrid authenticators offer agencies and overall industry leaders an overall solution to maintain US President’s Executive Order 14028 compliance and strengthen the protection of their most sensitive data.”
Users who leverage SafeNet eToken Fusion Series and Azure AD can benefit from:
- Using one single authenticator to securely access cloud apps and sign or encrypt digital documents from any desktop or mobile phone
- Protecting access to modern resources that support FIDO and “legacy” resources that support CBA
- Reducing the risk of data breaches by deploying phishing-resistant multi-factor authentication (MFA)
- Adopting FIDO while maintaining traditional PKI use cases like qualified digital signature and file encryption
The SafeNet eToken Fusion Series is available for use today. For a demo, visit Thales’s booth # N-5369 and Microsoft’s booth # N-6044 at RSA Conference 2023 (April 24 – 27 in San Francisco, USA). For more information, visit our landing page.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfill their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 77,0001 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.
PLEASE VISIT
Thales Group
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing9.6.2025 07:00:00 CEST | Press release
Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention taking place in Boston, USA, from 16-19 June. The company’s presentation is scheduled for Monday, June 16 at 16:45 ET in Room 153B. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). This announcement follows Azafaros’ recently completed and oversubscribed €132 million Series B financing round, which will support advancing nizubaglustat into pivotal clinical development. The company is on track to initiate two Phase 3 trials in GM1/GM2 gangliosidoses and NPC in 2025. Earlier this year, Azafaros reported positive topline results from its ongoing Phase 2 study evaluating n
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom